Trump Announces Phased Tariffs to Reshore Generic Drug Production

Donald Trump announced a phased tariff regime for generic medicines imported into the United States, effective August 1, 2026. Under the new policy, generic drugs will maintain a 0% tariff for two years, followed by a 100% duty in August 2028 and a 200% duty in August 2029.

The President stated the objective is to protect the American people and enhance national security by forcing pharmaceutical companies to reshore production to U.S. soil. This action follows an April Section 232 pharmaceutical proclamation that targeted branded, patented drugs. He noted that pharmaceutical facilities are being built across the country at an unprecedented level.

India, the largest exporter of generic medicines to the U.S., faces the most significant economic impact. However, a February trade agreement may allow for negotiated outcomes. Because generic drugmakers typically operate on thinner margins than branded firms, there are concerns they may be unable to absorb these costs, potentially leading to higher consumer prices.